Xencor News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.11.23	Xencor Reports Third Quarter 2023 Financial Results (Businesswire)
03.11.23	Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting (Businesswire)
31.10.23	Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023 (Businesswire)
26.10.23	Xencor CFO John Kuch To Retire In 2024 (RTTNews)
26.10.23	Xencor Announces Planned Retirement of Chief Financial Officer John Kuch (Businesswire)
27.09.23	Xencor to Present Multiple Posters at the SITC Annual Meeting (Businesswire)
19.09.23	Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors (Businesswire)
03.08.23	Xencor Reports Second Quarter 2023 Financial Results (Businesswire)
27.07.23	Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023 (Businesswire)
31.05.23	Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress (Businesswire)
08.05.23	Xencor Reports First Quarter 2023 Financial Results (Businesswire)
01.05.23	Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023 (Businesswire)
26.04.23	Xencor Appoints Nancy Valente, M.D., as Chief Development Officer (Businesswire)
17.04.23	Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023 (Businesswire)
14.03.23	Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023 (Businesswire)
23.02.23	Xencor Reports Fourth Quarter and Full Year 2022 Financial Results (Businesswire)
22.02.23	Ausblick: Xencor verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
16.02.23	Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023 (Businesswire)
07.02.23	Xencor to Present at the SVB Securities Global Biopharma Conference (Businesswire)
09.01.23	Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates (Businesswire)
05.01.23	Caris, Xencor Expand Collaboration To Develop XmAb Antibodies (RTTNews)
05.01.23	Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates (PR Newswire)
04.01.23	Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
12.12.22	Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting (Businesswire)
10.11.22	Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting (Businesswire)
07.11.22	Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study (Businesswire)
07.11.22	Xencor Reports Third Quarter 2022 Financial Results (Businesswire)
06.11.22	Ausblick: Xencor mit Zahlen zum abgelaufenen Quartal (finanzen.net)
03.11.22	Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting (Businesswire)
05.10.22	Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting (Businesswire)
09.09.22	Xencor Appoints Nancy Valente, M.D., to Board of Directors (Businesswire)
03.08.22	Xencor Reports Second Quarter 2022 Financial Results (Businesswire)
02.08.22	Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies (PR Newswire)
02.08.22	Ausblick: Xencor legt Quartalsergebnis vor (finanzen.net)
27.07.22	Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022 (Businesswire)
26.05.22	Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors (Businesswire)
05.05.22	Xencor Reports First Quarter 2022 Financial Results (Businesswire)
04.05.22	Ausblick: Xencor verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
28.04.22	Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022 (Businesswire)
08.04.22	Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Businesswire)
08.03.22	Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Businesswire)
23.02.22	Xencor Reports Fourth Quarter and Full Year 2021 Financial Results (Businesswire)
22.02.22	Ausblick: Xencor präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
16.02.22	Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022 (Businesswire)
02.02.22	Xencor to Present at Upcoming Investor Conferences (Businesswire)
11.01.22	Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones (Businesswire)
06.01.22	Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference (Businesswire)
13.12.21	AstraZeneca Elated On Calquence Data, IMGN's IMGN632 Appears To Be Promising In AML, XRTX On Watch (RTTNews)
12.12.21	Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting (Businesswire)
22.11.21	Zenas BioPharma Buys Worldwide Rights To Obexelimab From Xencor (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

Nachrichten zu Xencor Inc

Aktien Top/Flop

Meistgelesene Nachrichten